1. Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial 
Amit Arjyal, MBBS, Dr Buddha Basnyat, MD, Samir Koirala, MBBS, Abhilasha Karkey, MSc, Sabina Dongol, MSc, Krishna Kumar Agrawaal, MBBS, Nikki Shakya, MBBS, Kabina Shrestha, MBBS, Manish Sharma, MD, Sanju Lama, MBBS, Kasturi Shrestha, MD, Nely Shrestha Khatri, MBBS, Umesh Shrestha, MBBS, James I Campbell, MIBMS, Stephen Baker, PhD, Jeremy Farrar, FRCP, Marcel Wolbers, PhD, Christiane Dolecek, MD 
The Lancet Infectious Diseases 
Volume 11, Issue 6, Pages (June 2011)
DOI: /S (11)
Copyright © 2011 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*Two culture-positive patients in both the chloramphenicol and glatifloxacin groups were lost to follow-up before day 8.
The Lancet Infectious Diseases  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

3. Figure 2
Kaplan-Meier estimates for time to treatment failure, fever clearance, and relapse for culture-positive patients
The Lancet Infectious Diseases  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions